AI Extinction Fears and a Vision-Restoring Genetic Therapy Lead Today's Tech Roundup
A subscriber-only discussion will examine whether advanced AI could truly end humanity, featuring experts from MIT Technology Review. Separately, geneticist Yuancheng Lu's age-reversal technique, which repaired optic nerves in blind mice, has advanced to human clinical trials for vision restoration. The newsletter also notes that leading AI executives have jointly called for a slowdown in AI development.
The upcoming subscriber roundtable brings together three MIT Technology Review editors to examine claims from leading AI lab employees that advanced systems could pose an existential risk. The discussion will trace the origins of these fears and assess whether they represent genuine concern or speculative hype, while considering potential responses if the threats prove credible.
Separately, geneticist Yuancheng Lu has advanced his reprogramming technique, which restored vision in blind mice by repairing optic nerves, into human trials. Lu's personal connection to age-related blindness—including a genetic predisposition for macular degeneration—has driven his research at the Whitehead Institute, where he was recognized as a 2026 Innovator Under 35.
These parallel developments could reshape both public trust in AI and medical treatment for age-related vision loss. If the extinction debate gains traction, it may influence regulatory approaches and corporate accountability in AI development. Meanwhile, successful human trials of Lu's therapy could offer new hope to millions facing blindness, potentially transforming geriatric medicine. However, both areas remain uncertain, and outcomes will depend on continued research, clinical results, and how seriously policymakers and the public take these warnings.